Metastatic Colorectal Cancer — Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC
Citation(s)
Randomized Double-blind Phase III Trial of FOLF(HA)Iri vs FOLFIRI for Second or Third Line Therapy in Irinotecan-naïve Patients With Metastatic Colorectal Cancer